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BACKGROUND. This prospective trial was conducted to evaluate the outcome of 
patients treated with preoperative and postoperative chemotherapy, mastectomy, 
and irradiation for locoregionally advanced breast carcinoma. 
METHODS. Between June 1986 and September 1990, 71 patients received 2 cycles 
of doxorubicin that alternated with 2 cycles of cyclophosphamide, methotrexate, 
and 5-fluorouracil prior to mastectomy; irradiation was administered when the 
tumor was not amenable to surgical resection. Additional chemotherapy and ta- 
moxifen, in hormone receptor-positive tumors, was used after mastectomy. Post- 
operative irradiation was given on a selective basis for patients at high risk for 
locoregional disease recurrence. 
RESULTS. Although 5 patients (7%) had disease progression, clinical partial or 
complete tumor response to preoperative chemotherapy was noted in 46 patients 
(65%). Sixty-eight patients (96%) underwent mastectomy. With a median follow- 
up of 52 months, the relapse-free and overall survival rates at 5 years were 42% 
and 57%, respectively. Locoregional tumor recurrence occurred in 14 patients 
(20%), and 28 patients (39%) developed metastatic disease. Menopausal status, 
clinical presentation (noninflammatory vs. inflammatory), and American Joint 
Committee on Cancer clinical stage were independent covariates associated with 
patient outcome. 
CONCLUSIONS. Preoperative alternating chemotherapy, with the selective use of 
irradiation, resulted in significant locoregional disease regression and the success- 
ful integration of mastectomy into the therapeutic strategy. Locoregional tumor 
control and relapse-free and overall survival estimates for the approach described 
herein compared favorably with other contemporary reports for this condition. 
Cancer 1996; 7E2520-8. 0 1996 American Cancer Sociey. 
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or patients managed with mastectomy or irradia- F tion (RT) for locoregionally advanced breast carci- 
noma (LABC), disease relapse has been a common 
occurrence.l-" As a result, treatment of this condition 
evolved toward the integrated use of surgery, RT, and 
systemic therapy (e.g., chemotherapy). Although these 
treatments have been combined in different ways, the 
administration of systemic therapy prior to ablation 
of locoregional (LR) tumor (i.e., neoadjuvant therapy) 
has several possible advantages. With this approach, 
there existed the potential to provide prompt treat- 
ment of occult systemic disease (i.e., micrometas- 
tases), to reduce LR tumor burden to enhance the ef- 
ficacy of surgery and/or RT, and to eliminate concern 
regarding stimulated micrometastatic tumor growth 
after surgical removal of the primary tumor.4 On the 
basis of these principles, neoadjuvant chemotherapy 
was introduced into the management of LABC, and 
the initial experience with this approach resulted in 
favorable tumor response and patient o~tcome.""~  
Furthermore, the results achieved with neoadjuvant 
Chemotherapy may be enhanced by the use of addi- 
tional chemotherapy after surgical or radiotherapeutic 
treatment of the LR disease process.' 
During this time, the concept of alternating non- 
cross-resistant therapy emerged as a possible method 
to improve treatment efficacy.' This concept was 
based on the hypothesis that spontaneous somatic 
mutation of tumors occurred during the course of 
treatment. As a derivative of this hypothesis, an inverse 
relationship between tumor volume and the likelihood 
of cure with chemotherapy was assumed. This led to 
the conclusion that a combination of noncross-resis- 
tant chemotherapy used in a rapidly alternating fash- 
ion would have the greatest probability of eradicating 
all tumor cells within a heterogeneous population, and 
that the malignancy should be treated as early as pos- 
sible to increase the chance for cure. 
In the context of these observations, the North 
Central Cancer Treatment Group, in association with 
the Mayo Clinic, embarked upon a prospective trial 
that employed alternating noncross-resistant chemo- 
therapy as the initial treatment of LABC. The selection 
of chemotherapy was based on the results achieved 
with doxorubicin in the management of metastatic 
breast cancer," and the experience with the combina- 
tion of cyclophosphamide, methotrexate, and 5-flU0- 
rouracil in the adjuvant setting." After preoperative 
chemotherapy, mastectomy was incorporated because 
of the likelihood for residual LR disease," which might 
increase the risk of LR tumor recurrence and the emer- 
gence of chemotherapy-resistant tumor cells. RT was 
used to enhance LR disease control in patients with 
inflammatory carcinoma, and was selectively inte- 
grated into the treatment strategy for patients with 
noninflammatory disease on the basis of the histologic 
findings from the mastectomy specimen. 
PATIENTS AND METHODS 
Patient Characteristics 
Between June 1986 and September 1990, 71 women 
with histologically confirmed LABC were enrolled in 
a prospective study conducted by the North Central 
Cancer Treatment Group (NCCTG) in collaboration 
with the Mayo Clinic. These patients had one or more 
of the following clinical findings: tumor more than 5 
cm in diameter; tumor involvement of chest wall (ribs 
or intercostal or serratus anterior muscles) or skin (ip- 
silateral cutaneous edema, ulceration, or satellite nod- 
ules); clinically evident inflammatory carcinoma, l3  
ipsilateral fixed axillary adenopathy; or histologic 
evidence of ipsilateral internal mammary or supracla- 
vicular lymph node involvement. Additional criteria 
for trial eligibility included: age younger than 70 years; 
performance score of 0- 1 Is; adequate hepatic and re- 
nal function; and evaluable or measurable disease.14 
The presence of any of the following conditions pre- 
cluded study entry: prior breast cancer therapy; bilat- 
eral breast cancer; metastases to sites other than ipsi- 
lateral regional or supraclavicular lymph nodes; a leu- 
kocyte count of less than 4000/p,L; a platelet count of 
less than 1OO,OOO/pL; concurrent pregnancy or lacta- 
tion; or previous malignancy exclusive of nonmelano- 
matous skin carcinoma. Patients were considered 
technically operable if, in the opinion of the surgeon, 
all disease could be removed with primary closure 
(without cutaneous or muscular transposition) with- 
out anticipated microscopic or gross tumor residua. 
Of the 71 patients enrolled in this trial, all were 
included in the present analysis. No patient was ex- 
cluded due to trial ineligibility, cancellation, or loss to 
follow-up. The pretherapy clinical characteristics of 
the study group are summarized in Table 1. 
Evaluation and Treatment 
Prior to trial entry, patient evaluation was comprised 
of history, physical examination, complete blood cell 
count, chemistry profile, electrocardiography, chest 
radiography, mammography, radionuclide bone scan, 
and pregnancy test (if indicated). Treatment began 
(Fig. 1) after informed consent was obtained as speci- 
fied by Department of Health and Human Services 
and institutional guidelines. 
Preoperative chemotherapy was comprised of in- 
travenous doxorubicin, 75 mglm', followed 3 weeks 
later by the administration of cyclophosphamide (C), 
methotrexate (MI, and 5-fluorouracil (F). The CMF 
regimen consisted of cyclophosphamide, 600 mg/m" 
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methotrexate, 40 mg/m2, and 5-fluorouracil, 600 mg/ 
m2, administered intravenously on the first and eighth 
days of each &week cycle. Patient status was assessed 
at each chemotherapy session as specified by World 
Health Organization (WHO) guidelines. l4  Accordingly, 
clinical response was defined as follows: complete re- 
sponse, disappearance of all known disease; partial 
regression, 50% or greater decrease in tumor area or 
size; no change, less than partial regression without 
progressive disease; and progressive disease, 25% or 
greater increase in tumor size or appearance of new 
lesions. The WHO criteria were used to grade the acute 
toxicity of preoperative ~hemotherapy.’~ Treatment in 
accordance with protocol specification was discon- 
tinued if disease progression occurred. 
Dosage modification of all chemotherapeutic 
agents was made for severe nausea or vomiting (20% 
reduction), and for hepatic or hematologic toxicity. At 
the time of scheduled retreatment, therapy was de- 
\ 
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FIGURE 1. Treatment scheme. DOX: doxorubicin, CMF: cyclophospha- 
mide. methotrexate, 5-fluorouracil, RT: irradiation. ‘Inflammatory presen- 
tation; or residual tumor 1 5  cm diameter; or involvement of skin, fascia, 
2 4  axillary lymph nodes, or surgical rnargin(s). $Gross residual disease 
or microscopic involvement of surgical margin@). ‘If hormone receptor 
positive. 
layed if serum aspartate aminotransferase was more 
than 3 times the upper normal value, if serum total 
bilirubin was more than twice the upper normal value, 
if the leukocyte count was < 3000/pL, or if the platelet 
count was < lOO,OOO/pL. Modifications according to 
the hematologic nadir value of preceding cycles in- 
cluded a 20% dosage increase for a leukocyte count of 
> 3000/yL and a platelet count of > 100,000 pL, a 20% 
decrease for a leukocyte count of lOOO/pL to 1500/,~~L 
or a platelet count of 25,0001pL to 75,OOO/pL, and a 
30% decrease for a leukocyte count of < lO0OlpL or 
a platelet count of < 25,00O/yL. In addition, the dos- 
age of doxorubicin, methotrexate, and 5-fluorouracil 
was reduced for moderate (20% reduction) or severe 
(30% reduction) stomatitis or diarrhea. The dosage of 
methotrexate was reduced or discontinued in the pres- 
ence of renal toxicity. 
After two cycles of doxorubicin that alternated 
with two cycles of CMF, disease status was re-evalu- 
ated, and modified radical mastectomy (MRM) was 
performed in those patients regarded as technically 
operable. Patients with inflammatory presentation or 
those with histologic evidence of residual tumor that 
measured more than 5 cm in diameter, or with 
involvement of skin, fascia, 4 or more axillary lymph 
nodes, or surgical margin(s1 in the MRM specimen 
were considered at high risk for LR disease recurrence. 
For these patients, RT concurrent with two cycles of 
CMF was administered and followed with additional 
doxorubicin and CMF chemotherapy (Fig. 1). For pa- 
tients considered at low risk for LR recurrence, two 
postoperative cycles of doxorubicin that alternated 
with two cycles of CMF were given. 
When the tumor was not considered amenable to 
complete surgical resection after preoperative chemo- 
therapy, RT concomitant with two cycles of CMF was 
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used (Fig. 1 ) .  Thereafter, if MRM was performed with 
favorable margins (no evidence of gross tumor residua 
or microscopic involvement of surgical margins), three 
additional cycles of chemotherapy were administered. 
When MRM could not be performed or when unfavor- 
able margins existed after MRM, the patient went off 
study and was managed as indicated by clinical cir- 
cumstance. 
When given prior to mastectomy, the RT target 
volume consisted of the breast and chest wall, and 
the ipsilateral internal mammary, supraclavicular, and 
axillary lymph node regions. Megavoltage equipment 
was used to administer 50.4 Gray (Gy) in 28 daily frac- 
tions over 5.5 weeks; an additional 10-15 Gy in 5-8 
treatments was given to clinically apparent supracla- 
vicular or internal mammary adenopathy. Similar 
methods were used to administer postoperative RT, 
although the mastectomy scar received an additional 
10 Gy in 5-6 daily treatments. All patients in whom 
RT was initiated completed treatment and received 
the intended irradiation dosage. 
After completion of all therapy, patients were as- 
sessed every 3 months for 3 years, every 6 months 
during the next 2 years, and yearly thereafter. Sites 
of initial tumor progression were classified as local 
(ipsilateral chest wall), regional (ipsilateral supracla- 
vicular, infraclavicular, axillary or internal mammary 
lymph nodes), or distant (all other sites). The classifi- 
cation for any patient with simultaneous local or re- 
gional and distant tumor relapse was distant. 
Method of Analysis 
Relapse-free survival (RFS) and overall survival (0s) 
were determined from the date of registration to the 
date of treatment failure or death. For analysis of RFS, 
an event was defined as recurrence of breast carci- 
noma, and patients who died without evidence of dis- 
ease recurrence were censored; death from any cause 
was considered an event for evaluation of 0s. The 
method of Kaplan and Meier was used to estimate the 
duration of RFS and of 0S.l5 In analysis of outcome, 
the observed (crude) rate for the event under consider- 
ation was determined for each factor, and univariate 
comparisons of end points were made with the log 
rank statistic. l6 Multivariate analysis employed the Cox 
proportional hazard model to find the most significant 
factors related to outcome,” and variables were re- 
tained on the basis of the backward elimination proce- 
dure. A two-sided P value of 5 0.05 was considered 
significant. 
RESULTS 
Toxicity of Preoperative Chemotherapy 
Preoperative chemotherapy produced myelosuppres- 
sion in all but 1 patient (99%). Although 46 patients 
(65%) had a leukocyte nadir of < 2,0001pL (Grade 3 
or 4), only 3 patients (4.2%) had a minor-to-moderate 
(Grade 1 or 2) infectious complication and only 1 pa- 
tient (1.4%) experienced a major (Grade 3) infection. 
Thrombocytopenia (a platelet count of < 130,OOO/yL) 
occurred in 32 patients (45%), but a platelet nadir of 
< 50,OOO/p,L (Grade 3 or 4) was noted in only 6 patients 
(8%) and no hemorrhagic complications developed. 
No deaths occurred as a result of hematologic toxicity. 
Significant nonhematologic side effects were limited 
to vomiting (61%) that was severe (Grade 3) in 4 pa- 
tients (6%), and oropharyngeal mucositis and/or 
esophagitis that was evident in 33 patients (46%), but 
was moderate (Grade 2) in 8 patients (11%) and severe 
(Grade 3) in only 1 patient (1.4%). No life-threatening 
or lethal nonhematologic complications occurred. 
Among patients without tumor progression during 
preoperative chemotherapy (66 patients), 60 patients 
(91%) received 2 85% of the intended doxorubicin 
dose (median, 99%), and 2 85% of the planned 
amount of CMF chemotherapy was administered to 
50 patients (76%) (median, 98%). This compared favor- 
ably with the percentage intended dose administered 
thereafter, which for doxorubicin and for CMF was 2 
85% in 69% of patients (median, 94%) and 63% of 
patients (median, 79%), respectively. 
Response to Preoperative Chemotherapy 
As shown in Table 2, partial or complete clinical re- 
sponse to preoperative chemotherapy was observed 
in 46 patients (65%). Among 52 patients considered 
unresectable at presentation, 40 (77%) were deemed 
operable after preoperative chemotherapy and under- 
went MRM, whereas 10 patients also received RT with 
2 concurrent cycles of CMF prior to MRM. Eighteen 
of 19 patients amenable to surgical resection at pre- 
sentation were able to undergo MRM after chemother- 
apy. However, disease progression occurred in 5 pa- 
tients (7%), including l patient considered operable 
at the tim’e of registration, and 3 patients with nonin- 
flammatory carcinoma went off study because the ex- 
tent of LR disease progression (2 patients) or the devel- 
opment of distant metastases precluded surgical inter- 
vention (1 patient). Therefore, 68 of the 71 patients 
(96%) entered on the trial underwent MRM, and 53 
patients (75%) were managed solely with chemother- 
apy prior to surgical resection. Among these 53 pa- 
tients, the histologic findings of the MRM specimen 
placed 26 (49%) at high risk for LR tumor recurrence. 
For the 40 patients with noninflammatory clinical 
presentation, 37 underwent MRM; of these, 29 (78%) 
had a partial or complete response to preoperative 
chemotherapy. However, 10 patients (35%) were at 
high risk for LR disease recurrence based on findings 
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TABLE 2 
Clinical Response to Preoperative Chemotherapy 
Inflammatory Noninflammatory AU patients 
No. of No. of No. of 
Response patients % patients % patients % 
Complete 3 10 8 20 11 15 
Partial 14 45 21 53 35 49 
No cliatige 12 39 8 20 20 28 
Procression 2 6 3 8 5 7 
Relwsafrea survival - 
-- Overall survival 
I 
8 
from histologic examination of the MRM specimen. 
Likewise, 8 patients (22%) had no change to preopera- 
tive chemotherapy, and 4 patients (50%) remained in 
the high risk category after MRM. Therefore, of the 37 
patients with noninflammatory clinical presentation 
managed with MRM, 14 (38%) had histologic charac- 
teristics that placed the patient in the high risk cate- 
gory, and 13 patients received postoperative RT (one 
patient refused RT) on this basis. 
Disease Outcome 
With median follow-up of 52.2 months (range, 10.9 to 
89.9 months), tumor relapse occurred in 42 patients 
(59%), and 37 patients (52%) had died. The actuarial 
estimate of RFS and 0s for all patients at 5 years was 
42% and 57%, respectively (Fig. 2). Fourteen patients 
(20%) had LR recurrence as the initial and sole site of 
treatment failure, whereas 28 patients (39%) had initial 
disease relapse at a distant site(s). The distribution of 
initial sites of treatment failure according to clinical 
presentation, clinical response to preoperative chemo- 
therapy, and LR recurrence risk category are presented 
in Table 3.  Of note, the LR recurrence risk categories 
were not associated with LR tumor recurrence as an 
initial and sole site (perhaps because the high risk 
group received RT), but there was an association with 
metastatic disease relapse. 
Patient and tumor-related characteristics were eval- 
uated to determine the impact of selected pretherapy 
factors on treatment outcome. The variables selected 
for inclusion in a univariate analysis were menopausal 
status, clinical presentation, American Joint Committee 
on Cancer (AJCC) clinical ~ t age , '~  operability at presenta- 
tion, and the presence of fixed axillary adenopathy. Es- 
trogen receptor content was not included because the 
diagnostic biopsy did not recover a sufficient amount of 
tumor for quantification in a sizable proportion of pa- 
tients (42%). Although operability and fixed axillary ade- 
nopathy were not associated with either RFS or OS, all 
other characteristics approached or met statistical sig- 
nificance as factors predictive of disease outcome, as 
shown in Table 4. A significant difference in outcome 
between AJCC Stage IIIA and Stage IIIB was maintained 
with exclusion of AJCC Stage IIB and IV disease catego- 
ries (data not shown). 
Multivariate analysis preserved the significance of 
menopausal status, clinical presentation, and AJCC 
clinical stage as independent covariates. 
DISCUSSION 
The overall tumor stage distribution of patients with 
breast cancer has changed over the last several years. 
Indeed, the proportion of patients with LABC (i.e., 
AJCC Stage 111) has shown modest decline over time, 
and now accounts for approximately 7% of patients 
with newly recognized breast carcinoma.18 In addition 
to this relatively low incidence rate, LABC is also a 
heterogeneous condition in which patient characteris- 
tics and tumor-related factors have been predictive of 
disease outcome. For these reasons, prospective inves- 
tigations of this condition have been somewhat lim- 
ited, and the preferred management scheme for the 
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TABLE 3 
Initial Sites of Disease Relapse in Locoregionally Advanced Breast Carcinoma 
Distant metastasis Any relapse LR recurrence 
No. of No. of No. of No. of 
Characteristic patients patients % P value patients % Pvalue patients % P value 
Clinical presentation 
Inflammatory 31 8 26 14 45 22 71 
Noninflammatory 40 6 15 0.22 14 35 0.39 20 50 0.07 
Partial or complete 46 3 7 21 46 24 52 
No change 20 7 35 0.003a 6 30 0.23a 13 65 0.33a 
Clinical response 
Progression 5 4 80 1 20 5 100 
LR recurrence riskh 
Low 22 4 18 3 14 7 32 
High 46 8 17 0.94 24 52 0.002 32 70 0.003 
1.R: I.ocoregioiial. 
“Analysis restricted IO partial or complete response versus no change; results not affected by inclusion of patients with disease progression (data not shown) 
’Three patients who did not undergo mastectomy were excluded. 
All patients had intlammatoly presentation. 
TABLE 4 
Impact of Pretherapy Disease Characteristics on Outcome in Locoregionally Advanced Breast Carcinoma 
Relapse-free survival Overall survival 
No. of 



















































11.2 < 0.0001 
’ American Joint Committee on Cancer (AICC) Staging System.” 
patient with LARC has not been defined through con- 
temporaneous trials of a comparative study design. 
The present study was conducted to prospectively 
evaluate a therapeutic approach predicated on the hy- 
pothesis that tumor mutation to a drug-resistant state 
may occur during treatment.g Therefore, an alternat- 
ing noncross-resistant chemotherapy regimen was in- 
corporated into a multimodality program in an at- 
tempt to minimize the likelihood that treatment-re- 
fractory tumor clonogens would emerge. Furthermore, 
chemotherapy was administered as the initial compo- 
nent of a therapeutic approach designed to provide a 
reduction in LR tumor burden and prompt treatment 
of potential micrometastases. Although this study 
could not determine the relative efficacy of this ap- 
proach, the toxicity profile, clinical tumor response, 
and relapse-free survival and overall survival rates de- 
scribed herein were comparable to treatment pro- 
grams that administer chemotherapy in a conven- 
tional manner19-28 as well as in the setting of “hor- 
monal ~ynchronization.”~~-~’ 
The preoperative chemotherapy program used 
herein resulted in complete or partial tumor response 
in two-thirds of patients, which was comparable to 
2526 CANCER June 15,1996 I Volume 77 / Number 12 
results achieved in similar studies of preoperative che- 
motherapy for LABC.",24,26.27.29".JE.33 Although an associ- 
ation between clinical response and LR tumor control 
was observed, the metastatic relapse rate was not af- 
fected by clinical appraisal of tumor response at the 
primary site (Table 3). However, these observations 
must be viewed with caution because clinical response 
criteria may not reliably predict ultimate disease out- 
come.26.34 Furthermore, a trial of larger scope would 
be required to accurately evaluate the association of 
primary tumor response with the metastasis free 
rate."5 Nonetheless, it was noteworthy that tumor pro- 
gression was uncommon (7%) during preoperative 
chemotherapy, and three-quarters of patients with in- 
operable disease responded to preoperative chemo- 
therapy and the selective use of RT in a manner that 
allowed incorporation of mastectomy into the thera- 
peutic scheme. 
After initial chemotherapy (with or without preop- 
erative RT), mastectomy was incorporated because it 
was believed residual LR d i ~ e a s e ' ~ , ~ ~  might increase 
the risk for disease relapse. Although this approach 
produced satisfactory LR disease control, breast-con- 
serving surgery may be a feasible alternative for the 
patient with a favorable response to the preoperative 
chemotherapy ~ r o g r a m , ~ ' , ~ ~ , ~ ~  and merits consider- 
ation in future clinical trials for LABC. In an effort to 
improve disease control, RT was used in patients with 
clinical inflammatory breast cancer, and selectively on 
the basis of postmastectomy histologic findings in 
those with noninflammatory presentation. Although 
the number of patients available for analysis did not 
allow definitive conclusion, omission of RT in the low 
risk group did not result in an excessive rate of recur- 
rence at a LR site(s). Similarly, use of RT in the high 
risk cohort appeared to achieve satisfactory LR tumor 
control. However, analysis of initial, solitary sites of 
disease relapse may underestimate the likelihood of 
residual LR disease and the risk for tumor rec~rrence.~' 
Furthermore, all patients in the high risk group who 
experienced LR tumor recurrence presented with clin- 
ical inflammatory disease. Therefore, approximately 
one-quarter of those patients with clinical inflamma- 
tory breast carcinoma experienced LR recurrence as 
the first and only site of disease recurrence despite the 
combined use of chemotherapy, mastectomy, and RT. 
For this disorder, alternative methods of RT adminis- 
tration, such as accelerated hype r f r ac t iona t i~n ,~~ ,~~  or 
the use of innovative surgical or chemotherapeutic3' 
approaches require investigation in an attempt to im- 
prove LR tumor control. 
The influence of pretherapy characteristics on dis- 
ease outcome was also of interest and was evaluated 
within the context of this clinical trial. The overall clin- 
ical stage, assigned in accordance with the AJCC sys- 
tem,I3 was the most striking factor associated with re- 
lapse-free and overall survival. This confirmed the ob- 
servation of other i n v e ~ t i g a t o r s , ~ ~ . ~ ~  and provided 
further support for subdivision of the Stage I11 category 
and consideration of ipsilateral supraclavicular ade- 
nopathy as a metastatic site.'8.40 Likewise, the adverse 
impact of postmenopausal status and inflammatory 
clinical presentation on patient outcome confirmed 
These fac- 
tors should be considered in the development and 
interpretation of clinical trials addressing newer thera- 
peutic strategies for the management of LABC. 
This study represents one of the few clinical expe- 
riences of alternating noncross-resistant chemother- 
apy in the care of patients with high risk breast cancer. 
Although the design of a Belgium trial was similar to 
that reported herein,32 the Eastern Cooperative Oncol- 
ogy Group (ECOG) study of partially noncross-resis- 
tant chemohormonal therapy for premenopausal pa- 
tients with lymph node positive Stage I1 breast cancer"' 
was a prospective comparative trial that was in part 
based on assumptions central to the Goldie-Coldman 
hypothe~is.~ Although the ECOG investigation sug- 
gested a therapeutic benefit with the alternating ap- 
proach, the trial design included other variables that 
may explain this observation. Indeed, this finding may 
be attributed to the use of doxorubicin and/or fluox- 
ymesterone in the alternating, but not the conven- 
tional, regimen, rather than the method of treatment 
administration. Therefore, currently available clinical 
trials have not provided a definitive test of a hypothesis 
generated more than a decade ago. 
Although this report described patient outcome 
that followed a therapeutic strategy predicated on a 
certain model of tumor growth and treatment respon- 
siveness,' other hypotheses to explain chemotherapy 
resistance have been put forth. An alternative model 
suggested that a tumor is comprised of subclones with 
varied growth kinetics and different profiles of chemo- 
therapy re~istance.~' Adherence to this model sug- 
gested that the initial treatment should be adminis- 
tered in a continuous (i.e., uninterrupted) fashion 
against the more rapidly growing tumor subclone(s1. 
Thereafter, a noncross-resistant agent or combination 
effective against the slower growing and/or resistant 
subclone(s) should be given. Although this hypothesis 
has not been tested in the context of LABC, compara- 
tive clinical trials in lymph node positive, Stage I1 
breast cancer have been conducted. The Cancer and 
Leukemia Group B (CALGB) demonstrated an im- 
proved outcome when a doxorubicin-based combina- 
tion was administered after CMF with vincristine and 
predni~one.'~ However, as in the ECOG trial,41 the ben- 
the findings of prior investigations."- 71.24,25,29 
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eficial effect noted with sequential therapy may have 
been due to the addition of doxorubicin and/or fluox- 
yme s t er o n e . 
The Instituto Nazionale Tumori (Milan, Italy) pro- 
vided a more direct test of the alternating versus se- 
quential treatment approach and the assumptions de- 
rived from their respective biologic This 
randomized study compared two sequences of non- 
cross-resistant chemotherapy, namely, CMF alternat- 
ing with doxorubicin (alternating therapy) and doxo- 
rubicin followed by CMF (sequential therapy). Re- 
lapse-free survival and overall survival comparisons 
demonstrated improved results with the sequential 
therapy approach. Although both chemotherapy regi- 
mens included the same agents, dosages, treatment 
duration, and overall drug dose intensity, the doxoru- 
bicin dose intensity was higher for those patients as- 
signed to sequential therapy. Therefore, the advantage 
attributed to the sequential approach may have been 
related to doxorubicin dose intensity rather than the 
sequence of noncross-resistant chemotherapy that 
was administered. The results of ongoing clinical re- 
search efforts may resolve questions of this nature. 
In conclusion, the treatment strategy described 
herein provided a therapeutic outcome for patients with 
LABC that compared favorably with other contemporary 
investigations. Although this approach merits consider- 
ation for the care of these patients, further research ef- 
forts that adopt innovative s ~ r g i c a l , ~ ~ . ~ ~  radiotherapeu- 
tic?7,38 and systemic treatment3’~~~ measures are required 
to effect a much needed improvement for the outcome 
of patients with this condition. 
1. 
2. 
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